Teva executive sells shares worth over $70,000

TEL AVIV – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) executive Angus Grant, the company's EVP of Business Development, recently sold a portion of his holdings in the company. On August 9, Grant sold 4,065 ordinary shares at a price of $17.28 per share, totaling over $70,000.

The transaction was carried out under a pre-arranged trading plan, known as a Rule 10b5-1 plan, which was adopted by Grant on May 9, 2024. These plans allow company insiders to sell a predetermined number of shares at a predetermined time to avoid accusations of trading on nonpublic information.

In addition to the sale, Grant acquired 12,913 ordinary shares on the same day, which were related to the vesting of restricted share units. However, there was no monetary transaction associated with this acquisition, as it was part of a scheduled vesting event. The restricted share units were granted to Grant on August 9, 2023, and are set to vest annually over a four-year period.

Following the sale, Grant's direct ownership in Teva stands at 8,848 ordinary shares, while his total holdings, including the newly vested shares, amount to 38,739 shares. The ordinary shares mentioned in the report may be represented by American Depositary Shares, with each representing one ordinary share of Teva Pharmaceutical Industries Ltd.

Investors and followers of insider transactions often monitor these filings for insights into executive confidence and company health. Teva's stock performance and executive trading activity are closely watched as indicators of the pharmaceutical giant's ongoing business strategies and market position.

In other recent news, Teva Pharmaceuticals Industries Ltd. has reported a significant increase in its second-quarter revenue for 2024, reaching $4.2 billion, an 11% increase from the previous year. This rise was driven by the company's growth engines and generics business. Additionally, the company noted a non-GAAP earnings per share of $0.61, up from $0.56 in Q2 2023.

In light of these developments, Teva has updated its full-year revenue guidance to between $16 billion and $16.4 billion. The company is also on track to divest its TAPI division by the first half of 2025 and has received FDA approval for the biosimilar of Stelara, with a planned launch in February 2025.

Despite a decrease in Q2 2024 free cash flow to $324 million from $632 million in Q2 2023, primarily due to changes in working capital, Teva remains optimistic about the potential of its generics business and biosimilars portfolio. These recent developments underline Teva's commitment to its growth strategy and innovative pipeline.

InvestingPro Insights

As investors dissect the recent insider trading activity within Teva Pharmaceutical Industries Ltd., it's pertinent to consider the company's financial health and market performance. Teva's market capitalization stands at a robust $19.35 billion, reflecting its substantial presence in the pharmaceutical industry. Despite a negative P/E ratio of -42.83, the adjusted P/E ratio for the last twelve months as of Q2 2024 indicates a more favorable outlook at 22.29.

One InvestingPro Tip that stands out is Teva's strong return over the last year, with a year-to-date price total return of 63.6% and a 1-year price total return of 74.64%. This suggests that investors have been rewarding the company, potentially due to expectations of future growth or operational improvements. Additionally, Teva's revenue growth of 8.48% over the last twelve months as of Q2 2024, combined with a gross profit margin of 49.5%, underscores the company's ability to generate profits from its sales.

Another noteworthy InvestingPro Tip is that Teva is trading near its 52-week high, at 94.45% of this peak value. This price action could be reflective of investor sentiment and confidence in the company's prospects. For those interested in further insights, InvestingPro offers additional tips, including expectations of net income growth this year and the company's status as a prominent player in the pharmaceuticals industry.

For readers looking to delve deeper into Teva's financial metrics and potential investment strategies, InvestingPro provides a comprehensive set of tips, with a total of 12 additional tips available on their website.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.